A major study on the effects of Ampligen (Rintatolimod) on CFS provides added proof of Ampligen’s efficacy in ME/CFS following America’s Food & Drug Administration’s refusal to approve Ampligen for CFS in Dec 2009.
234 subjects with long-standing, debilitating CFS at 12 sites were given either twice weekly IV rintatolimod or a placebo.
Researchers reported that Ampligen increased exercise tolerance by 16.6%, reduced medication usage, improved most well-being scores and was safe.
